Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q3 FY21 results · Oct–Dec 2020
Ajanta Pharma reported revenue from operations of ₹748.74 crore (up 15.0% from Q3 FY20) and net profit of ₹176.63 crore (up 64.2% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 748.74 | 651.21 | +15.0% | 715.91 | +4.6% |
| Other income | 5.48 | 14.64 | −62.6% | 4.85 | +13.0% |
| Total income | 754.22 | 665.85 | +13.3% | 720.76 | +4.6% |
| Profit before tax | 215.47 | 175.10 | +23.1% | 249.24 | −13.5% |
| Net profit for the period | 176.63 | 107.55 | +64.2% | 170.22 | +3.8% |
| Attributable to shareholders of the company | 176.16 | — | — | — | — |
| EPS, basic (₹) | 20.41 | 12.33 | +65.5% | 19.51 | +4.6% |
| Net margin (%) | 23.6 | 16.5 | 23.8 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 733.16 | 530.55 | +38.2% | 676.51 | +8.4% |
| Other income | 2.90 | 51.17 | −94.3% | 86.24 | −96.6% |
| Total income | 736.06 | 581.72 | +26.5% | 762.75 | −3.5% |
| Profit before tax | 218.34 | 165.77 | +31.7% | 308.53 | −29.2% |
| Net profit for the period | 179.95 | 108.32 | +66.1% | 225.22 | −20.1% |
| EPS, basic (₹) | 20.80 | 12.41 | +67.6% | 25.81 | −19.4% |
| Net margin (%) | 24.5 | 20.4 | 33.3 |
Consolidated
- Filed with BSE
- 03 Feb 2021, 11:36 IST
- Board meeting
- 02 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Feb 2021, 11:36 IST
- Board meeting
- 02 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE